04702nam 2201261z- 450 991055779480332120231214133144.0(CKB)5400000000045439(oapen)https://directory.doabooks.org/handle/20.500.12854/68373(EXLCZ)99540000000004543920202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNew Prognostic and Predictive Markers in Cancer ProgressionBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (294 p.)3-03943-977-4 3-03943-978-2 Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.MedicinebicsscMSI2OSCCoral cancermusashi 2prognosisN-cadherinEMTbreast cancernew metastasiseribulinbloodbiomarkerbladder cancerimmune checkpoint inhibitorCD8+ T effector cellsmicroRNAbiomarkershead and neck cancerlaryngeal cancerpredictionmetastasislifestyle habitchemo-/radio resistancetherapeutic targetAKTARcastration-resistant prostate cancer (CRPC)MAPKmTORPI3Kprostate cancertherapeutic resistanceWNTmiRNAmelanomamelanoma resistance to MAPK/MEK inhibitorsresistance to immune checkpoint inhibitorsTNBCBRCA1/2HRRPDL1TILsPI3KCAPTENCTCsCSCpancreatic cancerK-RAS oncogeneoncogene dependencytargeted therapiesgenomic mutationstranscriptomicsmetabolomicsselenoproteinscancerHUB nodesmajor histocompatibility complex (MHC)human leukocyte antigen (HLA)antigen processing machinery (APM) moleculescarcinogenesistumor predispositioncancer immunotherapypheochromocytomaparagangliomahead and neck neoplasmshead and neck tumorsgenetic syndromesmutationshyperglycemiacardioncologynivolumabcytokinescardiotoxicityacetyltransferasecancer prognosisNAA10MedicineCostantini Susanedt1324162Budillon AlfredoedtCostantini SusanothBudillon AlfredoothBOOK9910557794803321New Prognostic and Predictive Markers in Cancer Progression3035971UNINA